Biomarker-driven access to crizotinib in ALK-, MET-, or ROS1-positive
- This topic has 0 replies, 1 voice, and was last updated 10 years, 2 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Biomarker-driven access to crizotinib in ALK-, MET-, or ROS1-positive malignancies in adults and children: Feasibility of the French National Acsé Program.
http://abstracts.asco.org/144/AbstView_144_131921.html
Viewing 1 post (of 1 total)
- The forum ‘New Developments’ is closed to new topics and replies.